

IN THE CLAIMS

Applicant has submitted a new complete claim set showing marked up claims with insertions indicated by underlining and deletions indicated by strikethroughs or double-bracketing. This listing of claims will replace all prior versions and listings of claims in the application.

1-79. (Cancelled)

80. (Currently amended) A method for inhibiting inflammation comprising, administering to a subject having an inflammatory disorder selected from the group consisting of asthma, gastrointestinal inflammation, pulmonary inflammation, kidney inflammation, ocular inflammation, pancreatic ~~inflammation~~ inflammation, genitourinary inflammation, systemic lupus erythematosus, dermatomyocytis, polymyositis, inflammatory neuropathies, ~~Wegener's granulomatosis~~ Wegener's granulomatosis, polyarteritis nodosa, polymyalgia, ~~rheumatica~~ rheumatica, temporal ~~ateritis~~ arteritis, Sjorgren's Sjogren's syndrome, Bechet's disease, Churg-Strauss syndrome, Takayasu's ~~arteitis~~ arteritis, neuroinflammatory disorders, allergic inflammation, dermatological inflammation, [[and]] skeletal inflammation, and inflammation from infection, an amount of a heterocyclic microsomal triglyceride transfer protein (MTP) inhibitor effective to inhibit the inflammation.


81. (Previously presented) The method of claim 80, wherein the inflammatory disorder is asthma.

82. (Previously presented) The method of claim 80, wherein the inflammatory disorder is gastrointestinal inflammation.


83. (Previously presented) The method of claim 80, wherein the inflammatory disorder is pulmonary inflammation.



84. (Previously presented) The method of claim 80, wherein the inflammatory disorder is kidney inflammation.
85. (Previously presented) The method of claim 80, wherein the inflammatory disorder is ocular inflammation.
86. (Previously presented) The method of claim 80, wherein the inflammatory disorder is pancreatic inflammation.
87. (Previously presented) The method of claim 80, wherein the inflammatory disorder is inflammatory neuropathy.
88. (Previously presented) The method of claim 80, wherein the inflammatory disorder is genitourinary inflammation.
89. (Currently amended) The method of claim 80, wherein the inflammatory disorder is systemic lupus erythematosus, dermatomyocytis, ~~Wegener's granulomatosis~~ Wegener's granulomatosis, polyarteritis nodosa, polymyalgia, ~~rheumatica~~ rheumatica, temporal ~~arteritis~~ arteritis, ~~Sjogren's~~ Sjogren's syndrome, Bechet's disease, Churg-Strauss syndrome, or Takayasu's ~~arteritis~~ arteritis.
90. (Previously presented) The method of claim 80, wherein the inflammatory disorder is polymyositis.
91. (Previously presented) The method of claim 80, wherein the inflammatory disorder is a neuroinflammatory disorder.
92. (Previously presented) The method of claim 80, wherein the inflammatory disorder is allergic inflammation.

93. (Previously presented) The method of claim 80, wherein the inflammatory disorder is dermatological inflammation.
94. (Previously presented) The method of claim 80, wherein the inflammatory disorder is skeletal inflammation.
95. (Previously presented) The method of claim 80, wherein the inflammatory disorder is inflammation from infection.
96. (Previously presented) The method of claim 80, wherein said MTP inhibitor is a compound according to Formula I:




wherein n is zero or 1;

P is  or a 5- or 6- membered heterocycle selected from the group consisting of:





wherein T and U are, independently, hydrogen or lower alkyl.

97. (Previously presented) The method of claim 80, wherein said MTP inhibitor is a compound according to Formula I:




wherein n is zero or 1;

P is or a 5- or 6- membered heterocycle selected from the group consisting of:



wherein T and U are, independently, hydrogen or lower alkyl.

98. (Previously presented) The method of claim 96, wherein P is



99. (Previously presented) The method of claim 80, wherein the administering is locally administering.
100. (Previously presented) The method of claim 80, wherein the administering is systemically administering.